Mechanism and Repository Study for the Red Cell Storage Duration Study
MARS
MARS
Sponsor study identifier
Secondary identifiers
observational
92
1 country
13
Study Start
July 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2016
Actual (reported)Study Completion
August 2016
Actual (reported)A large multicenter randomized controlled trial of approximately 1700 critically ill patients' status post complex cardiac surgery with sternotomy, called the Red Cell Storage Duration Study (RECESS), is currently ongoing. In the RECESS trial, study groups are randomized to either RBCs of less than or equal to 10 days storage time or to greater than or equal to 21 days. The primary outcome of RECESS is a change in multiple organ dysfunction score. Secondary outcomes in RECESS include all cause 28-day mortality, mechanical ventilation free days, and other clinical outcomes. The RECESS study presents a unique opportunity to investigate mechanisms associated with RBC storage duration in the context of clinical outcomes for well-characterized surgical study groups. The ancillary study described here is called the Mechanism and Repository Study (MARS) for RECESS. The MARS study will analyze the most commonly reported and hypothesized mechanisms considered to be associated with the RBC storage lesion and adverse outcomes in critically ill patients. Laboratories with expertise in RBC function, nitric oxide mechanisms, the coagulation cascade, microparticle analysis and immunology will each examine hypotheses addressing mechanisms potentially able to relate storage time to clinical outcomes in RBC transfusion recipients. At the conclusion of the study, the results will provide a much better understanding of how RBC storage age affects recipient RBC function, coagulation parameters, microparticle load and immune modulation. Perhaps most importantly, this study will also develop a large sample repository for future analysis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 16, 2012
Actual (reported)February 29, 2012
Actual (reported)July 2012
Date type not reportedThis date has not been verified as actual or estimated.
August 2016
Actual (reported)August 2016
Actual (reported)Comparison of pre- and post-operative lab values of vascular signaling, coagulation, microparticle counts, and inflammation and immune function
The primary objective of MARS is to compare post-operative values of these laboratory parameters between RBC-transfused RECESS subjects randomized to receive RBCs stored 10 days or less and RBC-transfused RECESS subjects randomized to receive RBCs stored 21 days or more.
Day 2, 6, 28 and 180
Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored no more than 10 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored at least 21 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
Subjects randomized in the RECESS study who did not receive any red blood cell units between randomization and 96 hours after the end of surgery
There are two study populations for MARS. One study population is adult subjects undergoing complex cardiac surgery who are participating in the RECESS trial. The other study population is a set of healthy adult volunteers.
Blood Systems Research Institute
San Francisco, California, 94118, United States
Emory University
Atlanta, Georgia, 30322, United States
Indiana/Ohio Heart
Fort Wayne, Indiana, 46804, United States
University of Iowa
Iowa City, Iowa, 52242, United States
St. Elizabeth's Medical Center
Boston, Massachusetts, 02135, United States
University of Minnesota - Fairview
Minneapolis, Minnesota, 55455, United States
Robert Wood Johnson Medial School
New Brunswick, New Jersey, 08903, United States
plasma, pRBCs, PBMCs
Philip Spinella, MD
Washington University School of Medicine
Philip Norris, MD
Vitalant Research Institute
Susan Assmann, PhD
Carelon Research
92 participants (actual enrollment reported by the registry).
First Submitted
February 16, 2012
First Posted
February 29, 2012
Study Start
July 2012
Date type not reportedThis date has not been verified as actual or estimated.
Measuring and Treating Brain Oxygen Levels in Open Heart Surgery
Contact the study team to confirm eligibility.
Vanderbilt University
Nashville, Tennessee, 37232, United States
University of Texas Southwestern
Dallas, Texas, 75390, United States
Texas Heart Institute
Houston, Texas, 77225, United States
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, 53215, United States
Froedtert Memorial Hospital
Milwaukee, Wisconsin, 53226, United States
Aspirus Heart & Vascular Institute
Wausau, Wisconsin, 54401, United States
Primary Completion
August 2016
Actual (reported)Study Completion
August 2016
Actual (reported)Last Updated
September 8, 2016
Record last verified: 2016-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: